ArticlePharmaceutics2022

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.

Bettina Gerner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.